SynoLife™/SynoLife™, Treatment Of Patients with pain associated with osteoarthritis (OA) of the knee | Reliance Life Sciences - LifeSciences - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
Sodium Hyaluronate is the sodium salt of hyaluronic acid (HA). HA is a carbohydrate, more specifically a mucopolysaccharide, occurring naturally in all living organisms. It can be several thousands of sugards (carbohydrates) long. When not bound to other molecules, it binds to water giving it a stiff viscous quality similar to ‘Jello’.
HA plays a vital role in development of cartilage, maintenance of the synovial fluid and regeneration of tendons. High concentrations of HA have been found in extracellular matrix (ECM) of all adult joint tissues, including the synovial fluid and outer layer of cartilage. In part because of its viscoelastic nature and ability to form highly hydrated matrices, HA acts in joint as a lubricant and shock absorber.
Viscosupplementation is a novel, safe and effective form of local treatment for osteoarthritis. Viscosupplementation in HA products helps to improve physiological environment in an osteoarthritic joint by supplementing shock absorption and lubrication properties of osteoarthritic synovial fluid. The rationale for using viscosupplementation is to restore the protective viscoelasticity of synovial hyaluronan, decrease pain, and improve mobility. The immediate benefit of viscosupplementation is relief of pain. Long-term benefits are believed to include return of joint mobility by restoration of transsynovial flow and, ultimately, metabolic and rheologic homeostasis of joint.
SynoLife™/SynoLife™ One is a formulation for viscosupplementation prepared from non-animal origin hyaluronic acid. It is a sterile, non-pyrogenic, elastoviscous fluid containing sodium hyaluronate stabilized with cross-linked derivative of sodium hyaluronate.
SynoLife™/SynoLife™ One contain sodium hyaluronate stabilized with cross-linked derivative of sodium hyaluronate (20 mg per ml) in buffered physiological sodium chloride solution (pH 7.2± 0.3). It contains high concentration of sodium hyaluronate which is pre-treated for improving the purity and stabilized with cross-linked sodium hyaluronate for improved stability and better rheology. The product is terminally sterilized by steam sterilization thus giving guaranteed sterility.
SynoLife™/SynoLife™ One is indicated for treatment of pain associated with osteoarthritis (OA) of the knee in patients who have not had an adequate response to non-pharmacologic conservative measures (e.g. weight loss, exercise, etc.) and simple analgesics (e.g. paracetamol and other nonsteroidal anti-inflammatory drugs).
SynoLife™ is available as a 2 ml (40 mg) injection containing 2% Sodium Hyaluronate in 2.25 ml glass syringe. It is also available in a pack of three injections.
SynoLife™ One is available as a 6 ml (120 mg) injection containing 2% Sodium Hyaluronate in 10 ml glass syringe.